Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease

Real-world evidence about mineralocorticoid receptor antagonist (MRA) use has been limited in chronic kidney disease, particularly regarding its association with hard renal outcomes. METHODS: In this retrospective cohort study, adult chronic kidney disease outpatients referred to the department of n...

Descripción completa

Detalles Bibliográficos
Autores principales: Oka, Tatsufumi, Sakaguchi, Yusuke, Hattori, Koki, Asahina, Yuta, Kajimoto, Sachio, Doi, Yohei, Kaimori, Jun-Ya, Isaka, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823908/
https://www.ncbi.nlm.nih.gov/pubmed/35026955
http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.18360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823908/
https://www.ncbi.nlm.nih.gov/pubmed/35026955
http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.18360

Ejemplares similares